Clinical trial NCT05880667: Adaptive Radiation for Abdominopelvic Metastases
Official title: Adaptive Radiation for Abdominopelvic Metastases (ARAM)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Neoplasm - Soft Tissue Pelvis Malignant Secondary
Malignant Neoplasm of Stomach
Lead sponsor: Fox Chase Cancer Center
Sponsor class: OTHER
First posted: 2023-05-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.

Detailed description: This is a dose-escalation study where the objective is to find the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of adaptive SBRT for abdominopelvic SBRT. There are 3 doses of interest 8Gy/fraction (level 1), 9Gy/fraction (level 2), and 10Gy/fraction (level 3). The starting dose will be level 2. We will use a Bayesian Optimal Interval Design (BOIN) to define dose escalation and de-escalation rules based on the proportion of patients experiencing a dose-limiting toxicity (DLT). DLT events are Grade 3 events possibly, probably, or definitely related to the study intervention.

Eligibility criteria: Inclusion Criteria:

1. Subjects must have histologically or cytologically confirmed cancer that is metastatic (all solid tumor types accepted), with at least one target lesion untreated by radiation, IR techniques, or growing in the abdomen or pelvis. Adjacent lymph nodes in the same region (5 cm or closer) constitute one active lesion. Target lesion must be measurable according to RECIST v 1.1. Previous systemic therapies are allowed.
2. Age \> 18 years.
3. ECOG performance status 0 or 1
4. Estimated survival of \>/= 12 months
5. Subjects must have normal organ and marrow function as defined below

   * Absolute neutrophil count \> 1,500/mcL
   * Platelets \> 100,000/mcL
   * Total bilirubin \< 2 mg/dL
   * AST/ALT (SGOT/SGPT) \< 5X ULN
   * Creatinine \< 1.5X ULN OR
   * Creatinine clearance ≥ 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal
6. Subjects must possess the ability to understand and willingness to sign a written informed consent and HIPAA consent document. Translation services including translation of informed consent documents will be provided, as feasible, to encourage diversity of inclusion of eligible patients.

Exclusion Criteria:

1. Subjects must not be experiencing toxicity due to prior therapy that has not resolved to ≤Grade 1 by study registration, with the exception of sensory neuropathy related to previous systemic therapy exposure, alopecia and fatigue.
2. Subjects must not be receiving any other investigational agents.
3. Subjects must not have known peritoneal carcinomatosis visible on imaging.
4. Subjects must not have known active solid tumors on imaging outside of abdomen/pelvis noted on screening imaging
5. Subjects must not have 6 or more active metastatic sites.
6. Subjects must not have had prior radiotherapy to any target metastatic lesion. Prior radiotherapy to non-target sites is allowed.
7. Subjects must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
8. Any condition or significant co-morbidity that prevents safe delivery of SBRT per the discretion of the treating physician(s).
9. Subjects must not be pregnant or breast-feeding. Refer to section 4.4 for further detail.

Primary outcomes:
measure: To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
Study officials:
affiliation: Fox Chase Cancer Center
name: Joshua Meyer, MD
role: PRINCIPAL_INVESTIGATOR
References: